Foghorn Therapeutics Inc.: 1 tracked 2026 layoff event(s), 65 workers counted, highest AI score 3.
AI score 3 (80% interval 3–4) · evidence grade D · US · Pharma / Chemicals
Stated reason: On September 25, 2026, following review of clinical data from the Phase 1 trial of FHD-909, Foghorn Therapeutics Inc. (the “Company”) and Eli Lilly and Company (“Lilly”) made the decision not to advance the trial into the expansion phase. Further collaboration activities pursuant to the collaboration agreement between the Company and Lilly are not anticipated. As a result, Foghorn is prioritizing resources toward the…
Why 3: Plant, store or site closure · Drivers: contrary evidence −0.6, industry AI exposure +0.5, role AI exposure +0.1
Signals: attribution 0.0, primary 0.0, exec 0.0, role exposure 0.455, industry exposure 0.712, AI investment 0.0, contrary 0.4 · named roles: Nursing Assistants, Registered Nurses
Headcount basis: 8-K text
Company AI financials (AI spending, revenue, earnings-call AI mentions) are coming soon to this page.
